Efficacy and safety of molnupiravir for COVID-19 patients

Eur J Intern Med. 2022 Aug:102:118-121. doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.

Authors

Maurish Fatima¹, Saleha Azeem¹, Junaid Saeed², Abia Shahid¹, Huzaifa Ahmad Cheema³; COVID-19 Therapeutics Study Group

Affiliations

¹ Department of Medicine, King Edward Medical University, Lahore, Pakistan.
² Department of Medicine, Nishtar Medical University, Lahore, Pakistan.
³ Department of Medicine, King Edward Medical University, Lahore, Pakistan. Electronic address: [email protected].

No abstract available

Keywords: COVID-19; EIDD-2801; MK-4482; Meta-analysis; Molnupiravir; SARS-CoV-2.

Publication types

Letter

MeSH terms

Antiviral Agents / adverse effects
COVID-19*
Cytidine / analogs & derivatives
Humans
Hydroxylamines

Substances

Antiviral Agents
Hydroxylamines
Cytidine
molnupiravir